$CLPT
ClearPoint Neuro, Inc. Stock $clpt

$clpt Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000128555022000003 Filed on March 09, 2022

Income Statement

Concept	2021	2020 Q4	2020
Revenue	$16.30M	$3.720M	$12.83M
YoY Change	27.05%	15.89%	14.34%
Cost Of Revenue	$5.008M	$1.430M	$3.709M
YoY Change	35.02%	53.76%	-3.16%
Gross Profit	$11.29M	$2.280M	$9.120M
YoY Change	23.8%	0.0%	23.58%
Gross Profit Margin	69.27%	61.29%	71.09%
Selling, General & Admin	$8.761M	$2.720M	$5.270M
YoY Change	66.24%	-3.55%	-41.83%
% of Gross Profit	77.59%	119.3%	57.79%
Research & Development	$8.985M	$1.830M	$4.686M
YoY Change	91.74%	107.95%	60.48%
% of Gross Profit	79.58%	80.26%	51.38%
Depreciation & Amortization	$159.0K	$160.0K	$334.0K
YoY Change	-52.4%	433.33%	138.57%
% of Gross Profit	1.41%	7.02%	3.66%
Operating Expenses	$17.75M	$4.550M	$9.956M
YoY Change	78.24%	22.97%	-16.89%
Operating Profit	-$13.37M	-$2.270M	-$6.220M
YoY Change	115.02%	59.86%	35.22%
Interest Expense	$973.0K	-$200.0K	$1.444M
YoY Change	-32.62%	-13.04%	-250.42%
% of Operating Profit
Other Income/Expense, Net	-$63.00K	$890.0K	$882.0K
YoY Change	-107.14%		8720.0%
Pretax Income	-$14.41M	-$1.580M	-$6.780M
YoY Change	112.54%	-4.24%	22.38%
Income Tax	$0.00		$0.00
% Of Pretax Income
Net Earnings	-$14.41M	-$1.580M	-$6.782M
YoY Change	112.47%	-4.24%	22.42%
Net Earnings / Revenue	-88.41%	-42.47%	-52.86%
Basic Earnings Per Share	-$0.69
Diluted Earnings Per Share	-$695.0K	-$94.44K	-$427.8K
COMMON SHARES
Basic Shares Outstanding	20.73M shares	16.87M shares
Diluted Shares Outstanding	20.73M shares

Balance Sheet

Concept	2021	2020 Q4	2020
SHORT-TERM ASSETS
Cash & Short-Term Investments	$54.11M	$20.10M	$20.10M
YoY Change	169.2%	252.63%	252.63%
Cash & Equivalents	$54.11M	$20.10M	$20.10M
Short-Term Investments
Other Short-Term Assets	$508.0K	$240.0K	$240.0K
YoY Change	111.67%	-33.33%	-33.33%
Inventory	$4.938M	$3.238M	$3.240M
Prepaid Expenses
Receivables	$2.337M	$1.881M	$1.880M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$61.89M	$25.46M	$25.46M
YoY Change	143.1%	145.3%	145.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.780M	$319.0K	$3.060M
YoY Change	-9.15%	-61.1%	273.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$644.0K	$59.00K	$650.0K
YoY Change	-0.92%	-91.81%	-9.72%
Total Long-Term Assets	$3.689M	$4.056M	$4.060M
YoY Change	-9.14%	161.68%	161.94%
TOTAL ASSETS
Total Short-Term Assets	$61.89M	$25.46M	$25.46M
Total Long-Term Assets	$3.689M	$4.056M	$4.060M
Total Assets	$65.58M	$29.52M	$29.52M
YoY Change	122.16%	147.43%	147.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$427.0K	$300.0K	$300.0K
YoY Change	42.33%	-69.07%	-69.07%
Accrued Expenses	$3.648M	$2.340M	$2.340M
YoY Change	55.9%	26.49%	26.49%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.753M	$3.200M	$3.200M
YoY Change	48.53%	-16.45%	-16.45%
LONG-TERM LIABILITIES
Long-Term Debt	$9.838M	$21.28M	$21.28M
YoY Change	-53.77%	928.02%	928.02%
Other Long-Term Liabilities	$2.203M	$2.660M	$2.660M
YoY Change	-17.18%	86.01%	86.01%
Total Long-Term Liabilities	$12.04M	$23.94M	$23.94M
YoY Change	-49.7%	584.0%	584.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.753M	$3.200M	$3.200M
Total Long-Term Liabilities	$12.04M	$23.94M	$23.94M
Total Liabilities	$16.79M	$27.14M	$27.14M
YoY Change	-38.12%	269.77%	269.75%
SHAREHOLDERS EQUITY
Retained Earnings		-$119.5M
YoY Change
Common Stock		$121.9M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$48.79M	$2.377M	$2.380M
YoY Change
Total Liabilities & Shareholders Equity	$65.58M	$29.52M	$29.52M
YoY Change	122.16%	147.43%	147.44%

Cashflow Statement

Concept	2021	2020 Q4	2020
OPERATING ACTIVITIES
Net Income	-$14.41M	-$1.580M	-$6.782M
YoY Change	112.47%	-4.24%	22.42%
Depreciation, Depletion And Amortization	$159.0K	$160.0K	$334.0K
YoY Change	-52.4%	433.33%	138.57%
Cash From Operating Activities	-$12.70M	-$2.400M	-$7.807M
YoY Change	62.67%	410.64%	173.93%
INVESTING ACTIVITIES
Capital Expenditures	$168.0K	-$40.00K	$41.00K
YoY Change	309.76%		-125.63%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$168.0K	-$40.00K	-$482.0K
YoY Change	-65.15%		201.25%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$46.79M		$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$46.88M	7.870M	$22.69M
YoY Change	106.57%	-9937.5%	305.21%
NET CHANGE
Cash From Operating Activities	-$12.70M	-2.400M	-$7.807M
Cash From Investing Activities	-$168.0K	-40.00K	-$482.0K
Cash From Financing Activities	$46.88M	7.870M	$22.69M
Net Change In Cash	$34.01M	5.430M	$14.40M
YoY Change	136.13%	-1087.27%	456.1%
FREE CASH FLOW
Cash From Operating Activities	-$12.70M	-$2.400M	-$7.807M
Capital Expenditures	$168.0K	-$40.00K	$41.00K
Free Cash Flow	-$12.87M	-$2.360M	-$7.848M
YoY Change	63.97%	402.13%	191.75%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Entity File Number EntityFileNumber	001-34822
CY2021	dei	Entity Registrant Name EntityRegistrantName	CLEARPOINT NEURO, INC.
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001285550
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	58-2394628
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	120 S. Sierra Ave.
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 100
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92075
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Solana Beach
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	City Area Code CityAreaCode	(888)
CY2021	dei	Local Phone Number LocalPhoneNumber	287-9109
CY2021	dei	Trading Symbol TradingSymbol	CLPT
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	361000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23690218	shares
CY2021	dei	Auditor Firm AuditorFirmId	677
CY2021	dei	Auditor Name AuditorName	Cherry Bekaert LLP
CY2021	dei	Auditor Location AuditorLocation	Tampa, Florida
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54109000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20099000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2337000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1881000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	4938000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	3238000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	508000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	244000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	61892000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	25462000	USD
CY2020Q4	us-gaap	Assets Assets	29518000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	427000	USD
CY2020Q4	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	353000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	125000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	539000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	319000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2241000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2736000	USD
CY2021Q4	us-gaap	Other Inventory Noncurrent OtherInventoryNoncurrent	519000	USD
CY2020Q4	us-gaap	Other Inventory Noncurrent OtherInventoryNoncurrent	589000	USD
CY2021Q4	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	265000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	59000	USD
CY2021Q4	us-gaap	Assets Assets	65581000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	300000	USD
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2604000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1595000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-6782000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	537000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	349000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	507000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	394000	USD
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	678000	USD
CY2020Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	562000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4753000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3200000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1939000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2446000	USD
CY2021Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	264000	USD
CY2020Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	215000	USD
CY2021Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	9838000	USD
CY2020Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	21280000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	16794000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	27141000	USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23665991	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23665991	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17047584	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17047584	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	237000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	170000	USD
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	182482000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	121729000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133932000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-119522000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	48787000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	2377000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	65581000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	29518000	USD
CY2021	us-gaap	Revenues Revenues	16299000	USD
CY2020	us-gaap	Revenues Revenues	12829000	USD
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	5008000	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	3709000	USD
CY2021	us-gaap	Gross Profit GrossProfit	11291000	USD
CY2020	us-gaap	Gross Profit GrossProfit	9120000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8985000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4686000	USD
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6919000	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5384000	USD
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8761000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	5270000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-13374000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-6220000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-63000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	882000	USD
CY2021	us-gaap	Interest Expense InterestExpense	973000	USD
CY2020	us-gaap	Interest Expense InterestExpense	1444000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14410000	USD
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.69
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20734236	shares
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15849667	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	4586000	USD
CY2020	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	3107000	USD
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1090000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	376000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-6782000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	2377000	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	14974000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	46785000	USD
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2078000	USD
CY2021	clpt	Warrant And Option Exercises Cash And Cashless WarrantAndOptionExercisesCashAndCashless	465000	USD
CY2021	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	224000	USD
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	599000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1090000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14410000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	48787000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14410000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-6782000	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	202000	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	27000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	159000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	334000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2078000	USD
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	325000	USD
CY2020	us-gaap	Paid In Kind Interest PaidInKindInterest	3000	USD
CY2021	us-gaap	Debt Instrument Increase Decrease Other Net DebtInstrumentIncreaseDecreaseOtherNet	0	USD
CY2020	us-gaap	Debt Instrument Increase Decrease Other Net DebtInstrumentIncreaseDecreaseOtherNet	896000	USD
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	100000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	890000	USD
CY2021	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	533000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	66000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-25000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1285000	USD
CY2021	clpt	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-432000	USD
CY2020	us-gaap	Depreciation Amortization And Accretion Net DepreciationAmortizationAndAccretionNet	216000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	658000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	818000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1714000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	25000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	264000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-113000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-459000	USD
CY2021	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	0	USD
CY2020	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	960000	USD
CY2020	clpt	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-128000	USD
CY2021	clpt	Increase Decrease From Contract With Customer Deferred Revenue IncreaseDecreaseFromContractWithCustomerDeferredRevenue	165000	USD
CY2020	clpt	Increase Decrease From Contract With Customer Deferred Revenue IncreaseDecreaseFromContractWithCustomerDeferredRevenue	-437000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12697000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7807000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	168000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	41000	USD
CY2021	clpt	Acquisition Of Licensing Rights AcquisitionOfLicensingRights	0	USD
CY2020	clpt	Acquisition Of Licensing Rights AcquisitionOfLicensingRights	441000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-168000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-482000	USD
CY2021	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	24258000	USD
CY2021	clpt	Proceeds From Issuance Of Paycheck Protection Program Loan ProceedsFromIssuanceOfPaycheckProtectionProgramLoan	0	USD
CY2020	clpt	Proceeds From Issuance Of Paycheck Protection Program Loan ProceedsFromIssuanceOfPaycheckProtectionProgramLoan	896000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	46785000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021	clpt	Proceeds From Stock Option And Warrant Exercises ProceedsFromStockOptionAndWarrantExercises	465000	USD
CY2020	clpt	Proceeds From Stock Option And Warrant Exercises ProceedsFromStockOptionAndWarrantExercises	376000	USD
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	224000	USD
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	0	USD
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	599000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	597000	USD
CY2020	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	USD
CY2021	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	0	USD
CY2020	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	2838000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	46875000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22692000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	34010000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	14403000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20099000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5696000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54109000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	20099000	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1578000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	40000.00	USD
CY2020	clpt	Net Transfers Of Reusable Components From Loaned Systems NetTransfersOfReusableComponentsFromLoanedSystems	100000	USD
CY2021	clpt	Net Transfers Of Reusable Components From Loaned Systems NetTransfersOfReusableComponentsFromLoanedSystems	100000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-3100000	USD
CY2021Q2	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	200000	USD
CY2020Q4	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	2600000	USD
CY2020Q4	clpt	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	2600000	USD
CY2021Q4	us-gaap	Cumulative Earnings Deficit CumulativeEarningsDeficit	-134000000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12700000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000	USD
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration Risks and Other Risks and Uncertainties</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company holds substantially all its cash and cash equivalents on deposit with financial institutions in the U.S. insured by the Federal Deposit Insurance Corporation. At December 31, 2021, the Company had approximately $48.4 million in bank balances that were in excess of the insured limits.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2021, one customer accounted for 15% of accounts receivable, and at December 31, 2020, one customer accounted for 11% of accounts receivable.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, one customer, who is a stockholder and a noteholder (see Note 6), and whose executive officer is a member of the Company’s Board of Directors, accounted for 18% of total revenue, and of 28% total revenue for the year ended December 31, 2020. Under the terms of the agreement with this customer, the Company bills and recognizes as revenue quarterly service fees of $0.7 million.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to granting credit, the Company performs credit evaluations of its customers’ financial condition, and generally does not require collateral from its customers. The Company will provide an allowance for doubtful accounts when collections become doubtful. The allowance for doubtful accounts at December 31, 2021 and 2020 was $0.3 million and $0.1 million, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to emerging companies in the medical device industry, including, but not limited to: new technological innovations; acceptance and competitiveness of its products; dependence on key personnel; dependence on key suppliers; dependence on third-party collaboration, license and joint development partners; changes in general economic conditions and interest rates; protection of proprietary technology; compliance with changing government regulations; uncertainty of widespread market acceptance of products; access to credit for capital purchases by customers; and product liability claims. Certain components used in manufacturing have relatively few alternative sources of supply and establishing additional or replacement suppliers for such components cannot be accomplished quickly. The inability of any of these suppliers to fulfill the Company’s supply requirements may negatively impact future operating results.</span></div>
CY2021Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	48400000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	300000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	3100000	USD
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated statement of operations for the year ended December 31, 2021 contains certain items formerly classified as service revenue that have been reclassified to product revenue. The accompanying consolidated statement of operations for the year ended December 31, 2020 has been conformed to the 2021 presentation.</span></div>
CY2021	us-gaap	Revenues Revenues	16299000	USD
CY2020	us-gaap	Revenues Revenues	12829000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	4938000	USD
CY2021Q4	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	2718000	USD
CY2020Q4	us-gaap	Inventory Work In Process And Raw Materials Net Of Reserves InventoryWorkInProcessAndRawMaterialsNetOfReserves	1485000	USD
CY2021Q4	clpt	Software Licenses SoftwareLicenses	210000	USD
CY2020Q4	clpt	Software Licenses SoftwareLicenses	193000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2010000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1560000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	3238000	USD
CY2021Q4	us-gaap	Other Inventory Noncurrent OtherInventoryNoncurrent	519000	USD
CY2020Q4	us-gaap	Other Inventory Noncurrent OtherInventoryNoncurrent	589000	USD
CY2021Q4	us-gaap	Inventory Gross InventoryGross	5457000	USD
CY2020Q4	us-gaap	Inventory Gross InventoryGross	3827000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2428000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2139000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1889000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1820000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	539000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	319000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	USD
CY2021Q2	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	200000	USD
CY2021Q2	us-gaap	Debt Related Commitment Fees And Debt Issuance Costs DebtRelatedCommitmentFeesAndDebtIssuanceCosts	200000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y9M
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	162000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	9838000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	10000000	USD
CY2021Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	USD
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.086
CY2021	us-gaap	Lease Cost LeaseCost	500000	USD
CY2020	us-gaap	Lease Cost LeaseCost	200000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	544000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	544000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	472000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	20542	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	19.01
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1350473	shares
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	486000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	500000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2546000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	100000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2446000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1806092	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.12
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	128399	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	18.09
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	563476	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.68
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1350473	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0095
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.10
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y5M4D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	8350000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1059253	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	10.05
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M3D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	7201000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	10.10
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y5M4D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	8350000	USD
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	294154	shares
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.09
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	128399	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.48
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	129291	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	2.01
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	2042	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	5.85
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	291220	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	5.38
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward	22918	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y10M9D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.5720
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.48
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.22
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2078000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1090000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	100000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	1200000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y10M24D
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	clpt	Percentage Valuation Allowance Deferred Tax Assets PercentageValuationAllowanceDeferredTaxAssets	1
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	4800000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	700000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-1999000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	-42000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3060000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1420000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1560000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-388000	USD
CY2021	clpt	Effective Income Tax Reconciliation Permanent Adjustments EffectiveIncomeTaxReconciliationPermanentAdjustments	114000	USD
CY2020	clpt	Effective Income Tax Reconciliation Permanent Adjustments EffectiveIncomeTaxReconciliationPermanentAdjustments	68000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-9000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	4000	USD
CY2021	clpt	Effective Income Tax Rate Reconciliation Net Operating Loss Write Off Amount EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteOffAmount	1649000	USD
CY2020	clpt	Effective Income Tax Rate Reconciliation Net Operating Loss Write Off Amount EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteOffAmount	1252000	USD
CY2021	clpt	Effective Income Tax Rate Reconciliation Paycheck Protection Program Loan Forgiveness Amount EffectiveIncomeTaxRateReconciliationPaycheckProtectionProgramLoanForgivenessAmount	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	29391000	USD
CY2020	clpt	Effective Income Tax Rate Reconciliation Paycheck Protection Program Loan Forgiveness Amount EffectiveIncomeTaxRateReconciliationPaycheckProtectionProgramLoanForgivenessAmount	-188000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4865000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	714000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26379000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21547000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2083000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2118000	USD
CY2021Q4	clpt	Deferred Tax Assets Tax Accrued Expense DeferredTaxAssetsTaxAccruedExpense	860000	USD
CY2020Q4	clpt	Deferred Tax Assets Tax Accrued Expense DeferredTaxAssetsTaxAccruedExpense	841000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	69000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	58000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	24564000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29324000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	24459000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	67000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	105000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	67000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	105000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29300000	USD

Files In Submission

Name	View Source	Status
0001285550-22-000003-index-headers.html	Edgar Link	pending
0001285550-22-000003-index.html	Edgar Link	pending
0001285550-22-000003.txt	Edgar Link	pending
0001285550-22-000003-xbrl.zip	Edgar Link	pending
clpt-20211231.htm	Edgar Link	pending
clpt-20211231.xsd	Edgar Link	pending
clpt-20211231x10kex21.htm	Edgar Link	pending
clpt-20211231x10kex231.htm	Edgar Link	pending
clpt-20211231x10kex31111.htm	Edgar Link	pending
clpt-20211231x10kex31211.htm	Edgar Link	pending
clpt-20211231x10kex3211.htm	Edgar Link	pending
clpt-20211231_cal.xml	Edgar Link	unprocessable
clpt-20211231_def.xml	Edgar Link	unprocessable
clpt-20211231_htm.xml	Edgar Link	completed
clpt-20211231_lab.xml	Edgar Link	unprocessable
clpt-20211231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLPT
ClearPoint Neuro, Inc. Stock $clpt

2021 Form 10-K Financial Statement

#000128555022000003 Filed on March 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLPT ClearPoint Neuro, Inc. Stock $clpt

2021 Form 10-K Financial Statement

#000128555022000003 Filed on March 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLPT
ClearPoint Neuro, Inc. Stock $clpt